top of page

About
- Corporate Overview
- Executive Management
Science
- Limbic Stem Cells & Exosome
- DNA Methylation Analysis
Services
Pipeline
- Cancer Detection
- Eye Related
Social Responsibility
Newsroom
Contact
More

Use tab to navigate through the menu items.

Newsroom

All Posts
Publication
News

Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target

Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target

Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target

International journal of molecular sciences vol. 19,10 3096 Chin-Sheng Hung, Sheng-Chao Wang, Yi-Ting Yen, Tzong-Huei Lee, Wu-Che Wen,...

Oct 10, 2018

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Hypermethylation of BEND5 contributes to cell proliferation andis a prognostic marker of colorectal cancer

Oncotarget vol. 8,69 113431-113443 Ruo-Kai Lin , Wan-Yu Hung, Yu-Fang Huang, Yu-Jia Chang, Chien-Hsing Lin, Wei-Yu Chen, Shih-Feng Chiu,...

Nov 1, 2017

Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer

Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer

Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer

Cell & bioscience vol. 4 46 Lin, Ruo-Kai , and Yi-Ching Wang * Lin, Ruo-Kai: Chief Technology Officer (CTO) of EG Biomed Abstract Cancer...

Aug 19, 2014

Contact

17 F., No. 3, Yuanqu St., Nangang Dist.,

Taipei City 115603, Taiwan (R.O.C.)

Email: service@udn-pharm.com

Tel: +886-2-2382-0330

Menu

Products & Services

Social Responsibility

bottom of page